AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CNS Pharmaceuticals, Inc. Director's Dealing 2019

Nov 8, 2019

35399_dirs_2019-11-08_477155a1-9d5d-4e4c-87f7-ad857408124e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CNS Pharmaceuticals, Inc. (CNSP)
CIK: 0001729427
Period of Report: 2019-11-07

Reporting Person: Priebe Waldemar (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9029000	Indirect

Footnotes

F1: Consists of: (i) 8,829,000 shares of common stock held by two limited liability companies; and (ii) 200,000 shares held by Houston Pharmaceuticals, Inc.